| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
α-Terpinyl acetate acts as an agonist of TRPV1 and TRPA1 channels, contributing to its analgesic and anti-inflammatory effects. It also inhibits NF-κB, reducing cytokine production. It disrupts bacterial cell membranes, showing antimicrobial activity. It also scavenges free radicals.
|
|---|---|
| ln Vitro |
α-Terpinylacetate, with an IC50 value of 10.4 μM, reduced the bupropion hydroxylation activity of P450 2B6. With a Ki of 7.6 μM, α-terpinylacetate was found to be a competitive inhibitor of P450 2B6 [2].
In vitro, α-terpinyl acetate shows antimicrobial activity against S. aureus and C. albicans with MIC values of 100-200 µg/mL. It inhibits LPS-induced NO production in macrophages with an IC50 of 30 µM. It scavenges DPPH radicals with an IC50 of 100 µM. It shows low cytotoxicity (IC50 > 500 µM). |
| ln Vivo |
In vivo, α-terpinyl acetate has anti-inflammatory effects in a carrageenan-induced paw edema model (50 mg/kg, p.o.) and analgesic effects in the hot plate test. In a mouse model of asthma, it reduced airway inflammation. It also showed anti-ulcer activity in rats.
|
| Enzyme Assay |
The in vitro antimicrobial assay uses broth microdilution. For anti-inflammatory, RAW 264.7 cells are treated with α-terpinyl acetate (1-100 µM) and LPS; NO and TNF-α are measured. TRPV1 activation is assessed by calcium imaging in HEK293 cells expressing TRPV1.
|
| Cell Assay |
For in vitro cell-based assays, HaCaT keratinocytes are treated with α-terpinyl acetate (1-100 µM) for 24 h; cell viability is measured by MTT. For wound healing, scratch assays are performed. For anti-inflammatory, macrophages are used.
|
| Animal Protocol |
In vivo anti-inflammatory studies in rats: rats are given α-terpinyl acetate orally (25, 50, 100 mg/kg) before carrageenan injection; paw volume is measured. For analgesic, mice are tested on hot plate. For ulcer studies, rats are given indomethacin to induce ulcers and treated with the compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are limited. In rats, after oral administration, the compound is rapidly absorbed and metabolized. Half-life is ~1.5 h. Bioavailability is moderate. Plasma protein binding ~70%. Excretion via urine.
|
| Toxicity/Toxicokinetics |
α-Terpinyl acetate has low toxicity (LD50 > 3000 mg/kg). It is not mutagenic. Skin and eye irritation may occur at high concentrations. It is considered safe as a flavor and fragrance ingredient.
|
| References | |
| Additional Infomation |
α-Terpineyl acetate is a p-menthane monoterpene compound. It has been reported to exist in perilla, asarum, and other organisms with relevant data. Terpineyl acetate is a metabolite found or produced in Saccharomyces cerevisiae.
α-Terpinyl acetate is a common fragrance and flavor compound. It has been studied for its potential anti-inflammatory and antimicrobial activities. No clinical trials have been conducted. It is available as a natural product for research. |
| Molecular Formula |
C₁₂H₂₀O₂
|
|---|---|
| Molecular Weight |
196.29
|
| Exact Mass |
196.146
|
| CAS # |
80-26-2
|
| PubChem CID |
111037
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
239.9±9.0 °C at 760 mmHg
|
| Melting Point |
220 °C
|
| Flash Point |
83.0±17.1 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.467
|
| LogP |
3.67
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
251
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C)OC(C1CCC(C)=CC1)(C)C
|
| InChi Key |
IGODOXYLBBXFDW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H20O2/c1-9-5-7-11(8-6-9)12(3,4)14-10(2)13/h5,11H,6-8H2,1-4H3
|
| Chemical Name |
2-(4-methylcyclohex-3-en-1-yl)propan-2-yl acetate
|
| Synonyms |
αTerpinyl acetate; α Terpinyl acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~509.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0945 mL | 25.4725 mL | 50.9450 mL | |
| 5 mM | 1.0189 mL | 5.0945 mL | 10.1890 mL | |
| 10 mM | 0.5095 mL | 2.5473 mL | 5.0945 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
